Stomach Cancer Trial, Recruiting NCT07441785 Sponsor: P. Herzen Moscow Oncology Research Institute Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT07441785
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a cancer of the stomach or the junction between the oesophagus (food pipe) and stomach (including certain types called Siewert I and II), where the cancer has not spread to distant parts of the body
  • People whose planned surgery involves removing the upper part of the stomach, with the goal of curing the cancer, performed at any point between 1 January 2025 and 31 December 2026
  • People whose surgery is planned to be carried out using any of the following approaches: open surgery, keyhole (laparoscopic) surgery, or robot-assisted surgery

Who may not be able to join:

  • People whose cancer has spread to other parts of the body, including those where cancer cells were found in the fluid around the abdominal organs during a previous assessment procedure
  • People who have another cancer diagnosed at the same time as the stomach or junction cancer
  • People whose cancer is specifically classified as an oesophagogastric junction Siewert I type malignancy (confirm with trial site)
  • People who require emergency surgery, or surgery that is not intended to cure the cancer
  • People who are having any additional surgical procedures beyond the curative stomach or oesophageal junction cancer surgery
  • People who have previously had surgery on the stomach or colon

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrey Ryabov, MD, PhD, P.Herzen Moscow Oncological Research Institute

Phone: +7 (495) 150-11-22

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
P. Herzen Moscow Oncology Research Institute
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

The structure and frequency of postoperative complications depending on the method of reconstruction, as well as neoadjuvant treatment; Overall survival; Frequency of local recurrence; Frequency of tumor progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov